Results from an exploratory biomarker analysis evaluating MET expression as a predictor of clinical response to rilotumumab (AMG 102) conducted on a previously reported Phase II study of rilotumumab in patients with locally advanced or metastatic gastric or gastroesophageal cancer, showed that treatment with the trial drug in combination with chemotherapy improved median overall survival (OS) in patients whose tumors exhibited high MET protein expression. Full results of the…

A subpopulation analysis of data from two phase III studies shows that
fidaxomicin (Dificid®,
Optimer Pharmaceuticals, Inc.)tablets offered faster diarrheal symptom improvement than oral vancomycin in patients with cancer being treated for clostridium difficile-associated diarrhea or…

Updated results from a Phase II study that showed treatment with blinatumomab (AMG 103/MT103,
Amgen, Inc/Micromet AG,) helped achieve a high-rate of complete response (CR) in 72% of adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL) treated in the study.



Acute lymphoblastic leukemia (ALL) is an aggressive cancer of…

The first head-to-head comparison of high throughput sequencing (HTS) using immunoSEQ™ (Adaptive Biotechnologies and traditional flow cytometry conducted in collaboration with Fred Hutchinson Cancer Research Center and the University of Washington Department…

For the first time, researchers at the University of California, San Diego have peered inside a living mouse cell and mapped the processes that power the celebrated health benefits of omega-3 fatty acids. More profoundly, they say their findings suggest it may be possible to manipulate these processes to short-circuit inflammation before it begins, or at least help to resolve inflammation before it becomes…

Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center have identified a new biomarker and therapeutic target for pancreatic cancer, an often-fatal disease for which there is currently no reliable method for early detection or therapeutic intervention. The study, supported by the…

The first cohort in a U.S. multi-center Phase 1b dose-escalation trial of a novel cancer-targeted molecular radiotherapeutic compound (I-131-CLR1404; Novelos Therapeutics, Inc.), in cancer patients with advanced solid tumors has been successfully completed. The first two-patient cohort was successfully dosed with approximately 20 mCi of I-131-CLR1404, triggering enrollment into the second cohort at approximately 40…

The UK National Institute for Health and Clinical Excellence (NICE), an independent organisation responsible for providing national (UK) guidance and standards on the promotion of good health and the prevention and treatment of ill health, has confirmed its decision not to approve cabazitaxel (Jevtana®;Black Triangle Drug; Sanofi) for use by the NHS. The decision followw an appeal from Sanofi and could effectively prevent…

Earlier today, the today European Commission confirmed that it has approved a conditional marketing authorization pixantrone (Pixuvri®, Cell Therapeutics), also known as BBR 2778, as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas.

 

Pixantrone is a novel…

In response to today's Perspective pieces published in the New England Journal Of Medicine (NEJM), the National Bone Health Alliance (NBHA), a public-private partnership bringing together the expertise and resources of its 42 members from the private and non-profit sectors to collectively advance bone health and prevent disease, commends the U.S. Food and Drug Administration (FDA)…